Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy

Inclusion Criteria: * Patients with a diagnosis of type 2 diabetes mellitus (T2DM). * HbA1c at baseline: ≥7.5 % to 8.5 %. * BMI between ≥26 and ≤35 kg/ m2. * Established Diabetic neuropathy diagnosed by nerve conduction study (NCS). Exclusion Criteria: * Patients diagnosed with type 1 diabetes mellitus or diabetes secondary to pancreatitis or resection of the pancreas. * Patients diagnosed with hemoglobinopathies, hemolytic anemia, or other diseases which interfere with HbA1c measurement. * Thyroid disease, cardiovascular disease, peripheral vascular disease, coagulopathy, moderate to severe liver disease (bilirubin\>1.5mg), or renal excretion ≤90ml/min. * Patients on medications which can result in a change of weight (orlistat, metformin, clozapine, gabapentin) and patients on medications that can interfere with glucose or lipid metabolism (corticosteroids, non-selective β-blockers, thiazides, etc.) * Treatment with any diabetes medications other than glimepiride prior to intervention. * Clinically significant cardiac abnormalities (diagnosed clinically, history, or by X-ray/ECG) that were not related to type 2 diabetes mellitus and that required further evaluation. * Patients with morbid obesity (BMI ≥ 40 kg/ m2). * History or current diagnosis of major depressive disorders or other psychiatric disorders. * Pregnant and breastfeeding women. * Patients with any inflammatory diseases. * Patients on cytochrome P450 inducers (e.g., rifampicin, phenobarbital, carbamazepine, p…